Cutaneous malignant melanoma (CMM; MIM #155601) comprises about 1% of all cancer cases in European populations, but its mortality is over 2% because of the propensity of this tumour to metastasise. Surveillance of CMM-prone individuals and populations should decrease the morbidity and mortality associated with this disease.

In approximately 5–12% of all melanoma cases, there is a family history of the disease, defined as having one or more affected first degree relatives. Germline mutations of CDKN2A, located on chromosome 9p21, cosegregate with affected cases in an estimated 20% of melanoma families worldwide (reviewed by Goldstein). CDKN2A encodes two different tumour suppressor proteins: the CDK4/6 cell cycle inhibitor p16INK4A from exons 1a, 2, and 3; and the MDM2 inhibitor p14arf from exons 1β, 2, and 3. The frequency of discovering a CDKN2A mutation within a family increases with the number of affected relatives, ranging from ~15% in families with two affected members, to 20–40% in those with three, and 70% in those with four or more (unpublished data from Hogg’s laboratory; Kefford and Mann). In addition, mutations in the CDK4 gene and polymorphisms in the MC1R gene have been implicated rarely in melanoma predisposition.

To date, mutations in the two major predisposition genes, CDKN2A and CDK4, account for melanoma susceptibility in less than half of all melanoma families, and the genetic bases of the disease in the remaining families have not been found. Gillanders et al recently provided strong evidence for another melanoma predisposition locus at chromosome 1p22. Current research in melanoma genetics is hindered by the allelic and locus heterogeneities, which render whole genome linkage analysis difficult. In addition, the sample sizes required to study the effects of weak or modifier alleles in a genetically heterogeneous population are large.

To address the problem of both allelic and locus heterogeneities, we have focused on populations that have undergone genetic bottlenecks and are genetically isolated. We hypothesise that familial melanoma patients within such populations arose from a limited number of founders and thus display a restricted number of melanoma predisposition alleles. These alleles are in linkage disequilibrium with adjacent markers. By searching for melanoma associated alleles and genotypes, we can isolate the predisposition loci and subsequently determine the variant or variants responsible.

Ashkenazi Jews originated in the Near East, and subsequently migrated to eastern and central Europe. Throughout history, the Ashkenazi Jewish population has experienced numerous bottlenecks which led to highly altered allele frequencies relative to the diverse ancestral population. This genetic drift is evident from the high incidences of multiple genetic disorders, attributable to founder mutations, and the population bottlenecks and the practice of endogamy have also decreased genetic variability.

The incidence of melanoma in Ashkenazi Jews is relatively high (table 1), but no CDKN2A mutations have been found in any Ashkenazi Jewish families. This population is therefore considered to be a promising setting for the identification of novel melanoma susceptibility genes. In this report we present the results of our search for CDKN2A mutations and polymorphisms, as well as 9p21 and 1p22 alleles and genotypes that are associated with melanoma, in our collection of Ashkenazi Jewish melanoma patients.

### METHODS

**Recruitment of patients and controls**

Fifty eight Ashkenazi Jewish patients with malignant melanoma (table 2; fig 1) were recruited to this study at the Centre for Medical Genetics in Tel Aviv, Israel.

Abbreviations: CMM, cutaneous malignant melanoma
described by Yakobson et al. Twenty of these reported a family history of the disease, defined as having at least one first degree relative affected by melanoma. All tumours were confirmed to be malignant melanoma by hospital pathologists. Genomic DNA was extracted from peripheral blood of all 58 patients.

The 86 control DNA samples were a kind gift from Dr Steve Narod (Toronto). They were obtained from individuals of Ashkenazi Jewish background who had no personal history of cancer, but may have had a family history of breast or ovarian cancer.

### Germline CDKN2A and CDK4 sequencing

For all samples, we sequenced exons 1 and 2 of CDKN2A as described by Liu et al., and exon 3 as described in Loo et al. We also amplified exon 1B using primers p14E1b-f and p14E1b-r (table 3), and sequenced using the same primers. We amplified exon 3 of CDKN2A using primers p16E3TMF and p16E3TMR (table 3) and the following amplification profile: 95°C for three minutes; 38 cycles of 95°C for 21 seconds, 66°C for 16 seconds, 72°C for 51 seconds; and 72°C for 22 minutes.

To screen for the two known melanoma associated mutations in CDK4 in patient samples, we amplified exon 2 of the gene using primers CDK4E2f and CDK4E2r (table 3), and sequenced the polymerase chain reaction (PCR) products using the same primers.

### Genotype analysis at the 9p21 and 1p22 chromosomal regions

To determine whether the chromosomal locus 9p21 and 1p22 are associated with melanoma, we carried out genotype analysis to search for alleles shared as a result of founder effect. The microsatellite markers used were D9S1749, 974, 942, 1748, 1604, and 171 for 9p21; and D15S35, 2779, 236, 2664, and 2726 for 1p22 (fig 2). We obtained primer sequences for all markers from the Genome Database (http://www.gdb.org/). We added the sequence GTTTCT to the 5` of the forward primer of D9S1749 according to the principles of the “PIGtailing” technique. This increased the clarity of the genotypes by ensuring that non-templated adenylation by Taq polymerase occurs to 100% of labelled PCR products. We carried out PCR (annealing at 58°C) and genotyping as described by Loo et al.

### Statistical analyses

For each marker, alleles were analysed if their frequencies were more than 10% in either patients or controls, and all other alleles were grouped together. We then compared the allelic frequencies in the patients vs the controls for each marker. In examinations of genotypic associations, genotypes made up of alleles with frequencies of more than 10% in either patients or controls were analysed, and all other genotypes were grouped together. We then compared the genotype frequencies in the patients vs the controls for each marker.

Genotype data were assessed for deviations from the Hardy–Weinberg Equilibrium separately for patient and control groups using the HWE program from the URL: http://linkage.rockefeller.edu/ott/linkutil.htm#HWE. To test whether specific alleles or genotypes were associated with the disease, the genotype data were analysed using the χ² test (EpiInfo6 from http://www.cdc.gov).

### RESULTS

Table 2 presents the descriptive statistics for the patient and control groups in the present study. The statistically significant difference seen between the sex distributions in the patient and control groups is probably because the control group consisted primarily of individuals seeking genetic
testing for breast cancer susceptibility, a disease that predominantly affects women. As melanoma predisposition is not inherited in a sex restricted manner, the difference in sex distribution is unlikely to affect subsequent analyses. Twenty of the 58 patients (34%, including four patients from two families) reported a family history, with clustering Twenty of the 58 patients (34%, including four patients from two families) reported a family history, with clustering

As the frequency of CDKN2A coding mutations does not account for all 9p21 linked families in other populations studied, we sought for a difference in allele and genotype frequencies between patients and controls, which may be indicative of candidate non-coding variants present in linkage disequilibrium with genetic markers in 9p21. The allele and genotype distributions for all six markers (fig 2) did not deviate from the HWE in either the patient or the control groups. Table 4 shows 9p21 allelic and genotypic frequency comparisons between patient and control groups, along with the calculated heterozygosities. Of the markers where the analyses were available, none showed allelic or genotypic associations with melanoma.

**Allelic and genotypic associations at the 1p22 locus**

Gillanders et al. provided strong evidence that a novel melanoma susceptibility locus is present at 1p22. We therefore searched for associations between 1p22 and melanoma cases in the Ashkenazi Jewish population. We undertook the same types of analyses for 1p22 as we did for 9p21, but found no significant allelic or genotypic associations with melanoma (table 5).

**DISCUSSION**

Multiple lines of evidence support a genetic basis for melanoma in Ashkenazi Jews. First, the incidence of cutaneous malignant melanoma in the Jewish population differs from that found in non-Jewish populations (table 1). Although differences in incidence rates among ethnic groups may reflect different environments and habits, they can also suggest that genetic backgrounds play a significant role in melanoma predisposition. Second, familial clustering suggests the segregation of mutant predisposition alleles. In our patient group, 20 of 58 patients (34%; including four patients

<table>
<thead>
<tr>
<th>Table 3</th>
<th>New primers used in this study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primer</strong></td>
<td><strong>Sequence (‘5’ to ‘3’)</strong></td>
</tr>
<tr>
<td>p14E1f</td>
<td>CGTGCACCAGTGAGCAGTATGCTA</td>
</tr>
<tr>
<td>p14E1r</td>
<td>GATATCGGACACACACTGTC</td>
</tr>
<tr>
<td>p16E3MF</td>
<td>CAGCCTACACATGTCGGGCG</td>
</tr>
<tr>
<td>p16E3MR</td>
<td>CAGAATTCACATGTCGGGCG</td>
</tr>
<tr>
<td>cdk4E2f</td>
<td>GGAGCTCTTCTGTGCTCG</td>
</tr>
<tr>
<td>cdk4E2r</td>
<td>CCAGTCGCCCACTAGTAA</td>
</tr>
</tbody>
</table>

bp, base pair; PCR, polymerase chain reaction.

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Association analyses for six microsatellite markers in 9p21</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Marker</strong></td>
<td><strong>Heterozygosities</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Patients</strong></td>
</tr>
<tr>
<td>DS1749</td>
<td>0.95</td>
</tr>
<tr>
<td>DS9974</td>
<td>0.95</td>
</tr>
<tr>
<td>DS9942</td>
<td>0.93</td>
</tr>
<tr>
<td>DS1748</td>
<td>0.90</td>
</tr>
<tr>
<td>DS1604</td>
<td>0.55</td>
</tr>
<tr>
<td>DS1717</td>
<td>0.75</td>
</tr>
</tbody>
</table>

*The analysis for DS1749 could not be carried out because there were no genotypes that were comprised of alleles that both had frequencies of >10%.
†*With the Bonferroni correction, the critical p value becomes 0.05/6 = 0.0083. As 0.021 is >0.0083, the result is not statistically significant.

3DPS1748 had too many genotypes that were comprised of alleles that both had frequencies of >10%; they therefore could not be analysed using the Epistat® function.
from two families) reported a family history of the disease, with some having multiple affected relatives (fig 1). Third, some individuals—such as the four (7%) in our series—are afflicted with multiple primary melanomas, or develop melanoma at an early age, observations that are also consistent with an underlying genetic predisposition. The early age of diagnosis of melanoma for some of the patients (for example, two patients diagnosed at age 22 in fig 1) possibly reflects accelerated tumour formation kinetics. Despite the evidence pointing to the cosegregation of genetic variants with melanoma predisposition in the Ashkenazi Jewish population, no such variants have so far been uncovered. In an earlier study, Yakobson et al found two CDKN2A mutations, Gly101Trp and Gly122Val, in two Israeli families, but neither is of Ashkenazi Jewish origin. Later, Yakobson et al uncovered a Val59Gly mutation in four melanoma pedigrees. The concordance of the microsatellites at this chromosomal region shows that the mutation in these four families is probably derived from one Mediterranean non-Ashkenazi founder. The genetic basis for melanoma susceptibility in the Ashkenazi Jewish population thus remains unknown and is the focus of the present study.

Analyses of mtDNA haplogroups and the non-recombining regions of the Y chromosome have shown that a major genetic drift has occurred in the history of the Ashkenazi Jewish population. Our strategy of taking advantage of the linkage disequilibrium between markers that resulted from recent founder effects should have enabled us to define genetic associations with melanoma at the 9p21 and 1p22 candidate loci. However, we were unable to find any allelic or genotypic associations between either of the two single nucleotide polymorphisms (exon 3 of CDKN2A) or the 11 microsatellite markers (9p21 and 1p22) and melanoma. There are several possible reasons for our findings; for example, it is possible that even within the Ashkenazi Jewish population, numerous melanoma predisposition variants exist, and our sample size did not allow us to find a definitive association that is statistically significant; furthermore, the melanoma predisposition alleles for melanoma are not located in the 9p21 or 1p22 chromosomal regions for the Ashkenazi population. These two possibilities are not mutually exclusive.

Investigation by Catalin et al (Catalin M, personal communication) on 24 Ashkenazi Jewish families with malignant melanoma and neural system tumour syndrome (MMNST) has also found no predisposing mutations in CDKN2A. These results, together with ours (82 families in all) show that CDKN2A is very unlikely to be the melanoma susceptibility locus for the Ashkenazi Jewish population. Further investigation should uncover a novel locus (or multiple loci) or environmental causes that underlie melanoma susceptibility of Ashkenazi Jews. The knowledge will allow the identification and surveillance of at-risk families, and thus decrease the morbidity and mortality associated with this disease.

ACKNOWLEDGEMENTS

We thank the individuals and families who participated in this study; Dr Steve Narod for control DNA samples; Dr Micha Barchana for information from the Israel National Cancer Registry; and members of the Hogg Lab for helpful discussions. JCYL is a recipient of an Ontario Graduate Scholarship in Science and Technology. ADP holds a Canada Research Chair in Genetics of Complex Diseases and is supported by Genome Canada. This work was supported by the National Cancer Institute of Canada (NCIC).

Authors’ affiliations

J C Y Loo, Department of Medical Biophysics, University of Toronto, Toronto, Canada
A D Paterson, Program in Genetic and Genomic Biology, Hospital for Sick Children, Toronto
A Hao, M Shenann, Department of Clinical Sciences, University of Toronto
H Peretz, Laboratory of Clinical Biochemistry, Tel Aviv University, Sourasky Medical Centre, Tel Aviv, Israel
Y Sidi, E Yakobson, Molecular Cell Biology Laboratory, Department of Internal Medicine "C", Sheba Medical Centre, Tel-Hashomer, Israel
D Hogg, Department of Medicine, University of Toronto

Competing interests: none declared

Correspondence to: Dr David Hogg, University of Toronto, Medical Sciences Building, Room 7368, Toronto, Ontario, MSS 1A8 Canada; david.hogg@utoronto.ca

Received 17 September 2004
Revised version received 20 December 2004
Accepted for publication 21 December 2004

REFERENCES


Table 5 Association analyses for six microsatellite markers in 1p22

<table>
<thead>
<tr>
<th>Marker</th>
<th>Patients</th>
<th>Controls</th>
<th>χ²</th>
<th>df</th>
<th>p Value</th>
<th>Df</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>D1S435</td>
<td>0.75</td>
<td>0.70</td>
<td>5.78</td>
<td>3</td>
<td>0.123</td>
<td>6</td>
<td>0.730</td>
</tr>
<tr>
<td>D1S2779</td>
<td>0.70</td>
<td>0.65</td>
<td>1.65</td>
<td>2</td>
<td>0.437</td>
<td>3</td>
<td>0.625</td>
</tr>
<tr>
<td>D1S236</td>
<td>0.82</td>
<td>0.85</td>
<td>2.38</td>
<td>3</td>
<td>0.497</td>
<td>2</td>
<td>0.901</td>
</tr>
<tr>
<td>D1S2664</td>
<td>0.74</td>
<td>0.70</td>
<td>1.55</td>
<td>3</td>
<td>0.670</td>
<td>3</td>
<td>0.635</td>
</tr>
<tr>
<td>D1S2726</td>
<td>0.68</td>
<td>0.76</td>
<td>4.57</td>
<td>3</td>
<td>0.205</td>
<td>6</td>
<td>0.366</td>
</tr>
</tbody>
</table>

Accepted for publication 21 December 2004
Revised version received 20 December 2004
Correspondence to: Dr David Hogg, University of Toronto, Medical Sciences Building, Room 7368, Toronto, Ontario, MSS 1A8 Canada; david.hogg@utoronto.ca

Received 17 September 2004
Revised version received 20 December 2004
Accepted for publication 21 December 2004

REFERENCES


